DBV TECHNOLOGIES SA-SPON ADR (DBVT)

US23306J2006 - ADR

3.19  +0.14 (+4.59%)

Premarket: 3.21 +0.02 (+0.63%)

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (12/20/2024, 8:04:52 PM)

Premarket: 3.21 +0.02 (+0.63%)

3.19

+0.14 (+4.59%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-512.9%
Sales Q2Q%-49.52%
CRS7.3
6 Month-34.23%
Overview
Earnings (Last)07-30 2024-07-30/amc
Earnings (Next)N/A N/A
Ins Owners0.15%
Inst Owners41.39%
Market Cap65.45M
Shares20.52M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.86
Short Float %N/A
Short Ratio0.37
IPO03-29 2012-03-29
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DBVT Daily chart

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 106 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

Company Info

DBV TECHNOLOGIES SA-SPON ADR

Batiment IRO, 107 Av. de la Republique

Chatillon AUVERGNE-RHONE-ALPES 92120

P: 33155427878

CEO: Daniel Tasse

Employees: 106

Website: https://www.dbv-technologies.com/

DBVT News

ChartMill News Image11 days ago - ChartmillThese stocks are moving in today's after hours session

Stay updated with the stocks that are on the move in today's after-hours session.

ChartMill News Image11 days ago - ChartmillThese stocks are gapping in today's session

Thursday's session: gap up and gap down stocks

ChartMill News Image12 days ago - ChartmillThese stocks are moving in today's after hours session

Top movers in Wednesday's after hours session

News Image12 days ago - DBV Technologies S.A.DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
News Image12 days ago - DBV Technologies S.A.DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 –...

News Image12 days ago - DBV Technologies S.A.DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans

Châtillon, France, le 11 décembre (22 :05 CEST) 2024 DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch...

DBVT Twits

Here you can normally see the latest stock twits on DBVT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example